So from what i can tell the legal stuff will take years and no guarantee of a positive outcome, the US market continues to get undercut by generics, and Europe/ROW is growing slowly. We have ~$300 million in cash for now, but remain cashflow negative.
Our drug is approved, it's safe and effective, and we have EU exclusivity for 15 years, but no one seems to be able to sell it or get it reimbursed.
Does that about sum it up?
At this point all Denner and his team should be doing is figuring out how to finagle a buyout of $4-5 per share, and nothing else IMO. Surely BP could leverage their immense leverage and improve all facets of the Vascepa business.
My average is $2.57 and even that seems like a huge premium right now to be honest, based on our current doldrums.
Market Data 
Markets 
AI
